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Promotion of good mental health, prevention and early intervention before/at the onset of 
mental disorders improve outcomes. However, the range and peak ages at onset for mental 
disorders are not fully established. To provide robust, global epidemiological estimates of age 
at onset for mental disorders, we conducted a PRISMA/MOOSE-compliant systematic review 
with meta-analysis of birth cohort/cross-sectional/cohort studies, representative of the general 
population, reporting age at onset for any ICD/DSM-mental disorders, identified in 
PubMed/Web of Science (up to 16/05/2020) (PROSPERO:CRD42019143015). Co-primary 
outcomes were the proportion of individuals with onset of mental disorders before age 14, 18, 
25, and peak age at onset, for any mental disorder and across ICD-11 diagnostic groups. Across 
192 studies (n=708,561), the proportion of individuals with onset of any mental disorders 
before age 14, 18, 25, and peak age were 34.6%, 48.4%, 62.5%, and 14.5 years (k=14, 
median=18, interquartile range (IQR)=11-34). For specific disorders, results were as follows: 
neurodevelopmental disorders: 61.5%, 83.2%, 95.8%, 5.5 years (k=21, median=12, IQR=7-
16), anxiety/fear-related disorders: 38.1%, 51.8%, 73.3%, 5.5 years (k=73, median=17, 
IQR=9-25), obsessive-compulsive/related disorders: 24.6%, 45.1%, 64.0%, 14.5 years (k=20, 
median=19, IQR=14-29), feeding/eating disorders/problems: 15.8%, 48.1%, 82.4%, 15.5 years 
(k=11, median=18, IQR=15-23), conditions specifically associated with stress disorders: 
16.9%, 27.6%, 43.1%, 15.5 years (k=16, median=30, IQR=17-48), substance use 
disorders/addictive behaviors: 2.9%, 15.2%, 48.8%, 19.5 years (k=58, median=25, IQR=20-
41), schizophrenia-spectrum disorders/primary psychotic states: 3%, 12.3%, 47.8%, 20.5 years 
(k=36, median=25, IQR=20-34), personality disorders/related traits: 1.9%, 9.6%, 47.7%, 20.5 
years (k=6, median=25, IQR=20-33), and mood disorders: 2.5%, 11.5%, 34.5%, 20.5 years 
(k=79, median=31, IQR=21-46). No significant difference emerged by sex, or definition of age 
of onset. Onset of disorders emerged on a time continuum, from 
neurodevelopmental/separation anxiety/phobias, to social anxiety/obsessive-
compulsive/trauma-related disorders, followed by anxiety/eating/substance-related/mood 
disorders, and finally personality disorders and schizophrenia. These results inform the timing 
of good mental health promotion/preventive/early intervention, updating the current mental 




Individuals with mental disorders have a decreased life expectancy of 10-15 years in 
comparison with the general population[1–4]. Early interventions at first onset of mental 
disorders can improve several outcomes[5, 6]. Primary indicated prevention in those at 
clinical high risk has the potential to alter the course of the disorder and improve 
outcomes [7–9]. For example young people with attenuated symptoms for psychosis[10–
13]) and functional impairments accumulate several risk factors and have a 25% 
probability of developing the disorder over 3 years[14]. Clinical care for these individuals 
is typically implemented in specialised clinical services[15–18] and has the potential to 
delay or impede transition to psychosis (the efficacy of preventive interventions awaits 
more robust evidence[19–21]) Targeted preventive approaches involve screening 
programs in asymptomatic individuals who have significant risk factors for certain 
psychiatric disorders[22–24] (primary selective prevention[7, 8]) or public health 
campaigns in the general population (primary universal prevention)[7, 8, 25]. To date, 
these initiatives have been mostly piloted for young people with emerging severe mental 
disorders[8]. A further complementary approach is to promoted good mental health, as 
opposed to preventing mental-ill health[7, 26, 27].  
Although promotion of good mental health, prevention and early intervention can be 
implemented lifespan, the benefits are maximal when young people are targeted at around 
the time of onset of mental disorders. Unfortunately, the peak ages and ranges at onset 
for mental disorders are not fully established, with conflicting findings across[28, 29] and 
within studies[30], partly due to methodological limitations, including selection biases in 
recruitment for clinical studies[31]. General population-level studies (birth cohort, cross-
sectional or incidence studies) provide the most robust onset age estimates[31]. However, 
to date, no comprehensive epidemiologically-sound, large-scale meta-analysis has pooled 
data from these population-based studies that are representative of the general population 
to estimate the peak age at onset across the globe and proportion of individuals with 
mental disorders at certain age points. This study aimed to fill this gap aiming to optimize 
timely intervention, prevention and promotion of good mental health opportunities at the 






A study protocol was registered and is publicly available on PROSPERO 
(CRD42019143015). We performed a systematic review adhering to the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 
recommendations[32] (e-table 1) and the Meta-analysis of Observational Studies in 
Epidemiology (MOOSE) guidelines (e-table 2)[33]. 
At least two authors (MO, ER, LS, MS, all MDs) independently searched PubMed and 
Web of Science using the following terms: “age at onset” (topic) and “mental disorder” 
(topic), plus “birth cohort” (topic) and “mental disorder” (topic), plus “incidence” (topic) 
and “mental disorder” (topic), without restriction to the type of mental disorder. 
Additionally, reviews and reference lists of included studies were manually searched. The 
literature was searched from database inception until 16/05/2020. Hits were first screened 
at the title/abstract level, then full texts of the remaining articles were assessed, recording 
reasons for exclusion (as per the criteria noted below). 
 
Inclusion and exclusion criteria 
Included were: i) original birth cohort, or cross-sectional studies retrospectively assessing 
age at disorder onset, or prospective incidence studies[31], ii) focusing on the general 
population, iii) assessing age at onset of mental disorders, defined according to 
International Classification Diseases (ICD) or Diagnostic and Statistical Manual (DSM)-
any version criteria, or by established psychometric instruments with validated cut-offs 
that defined ICD/DSM diagnostic categories, iv) written in English. 
Excluded were: i) studies sampling clinical groups that were not representative of the 
general population, ii) studies assessing the prevalence, not onset age of mental disorders, 




The following variables were extracted into pre-defined excel spreadsheets: DOI/PMID, 
author, publication year, country of study, study design (birth cohort, cross-sectional, 
incidence studies, all representative of the general population), name of the cohort (if 
available), ICD/DSM diagnostic criteria, onset definition (first symptoms, first diagnosis, 
first hospitalisation), specific type of mental disorder, sample age range, number of 
participants, number of cases developing incident mental disorders. Age at onset of 
mental disorders was extracted as available in each of the included studies (see statistics). 
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Data extraction was performed independently by the same two authors who performed 
the literature screening. 
 
Study quality assessment 
To the best of our knowledge, no quality assessment measure has been validated for the 
type of studies included in the current meta-analysis. Therefore, risk of bias was evaluated 
with an ad-hoc list of criteria derived from the Newcastle-Ottawa scale (NOS)[34], which 
included the definition of onset age of the mental disorder, diagnostic criteria employed, 
and study design. However, since these criteria were not validated, they were not 




Study-defined age at onset of mental disorders encompassed: (i) mean and standard 
deviation (SD), percentiles, median and/or interquartile range (IQR) of age at disorder 
onset; (ii) proportion of cases of a sample whose age at disorder onset fell into a certain 
age group, (iii) number of incident cases developing mental disorders, separately for age 
groups (e.g., for national registries). 
We defined co-primary outcomes as the proportion of individuals with age at disorder 
onset of any and specific mental disorder groups before 14, 18 and 25 years old, and peak 
age at onset for any mental disorder and for each diagnostic group. Diagnostic groups 
matched all 19 ICD-11 diagnostic blocks under “Mental, behavioural or 
neurodevelopmental disorder”, namely neurodevelopmental disorders, schizophrenia-
spectrum and primary psychotic disorders, catatonia, mood disorders, anxiety and fear-
related disorders, obsessive-compulsive or related disorders, disorders specifically 
associated with stress, dissociative disorders, feeding or eating disorders, elimination 
disorders, disorders of bodily experience, disorders due to substance use or addictive 
behaviour, impulse-control disorders, disruptive behaviour or dissocial disorders, 
personality disorders and related traits, paraphilic disorders, factitious disorders, 
neurocognitive disorders, disorders associated with pregnancy childbirth or puerperium. 
Individual studies adopted different age subgroupings and age ranges. To our knowledge, 
there is no standard method to pool such varying descriptive statistics of the distribution 
of a variable (age at onset of mental disorders) when the variable of interest follows a 
non-normal distribution and/or is heterogeneously censored. Therefore, we have 
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developed an ad-hoc method to meta-analyse these estimates. To assess these co-primary 
outcomes, we first estimated the histogram of the age at disorder onset that minimized 
the sum of squared errors (SSE) of the study-reported data. From this histogram, we then 
derived peak age at onset, as well as the proportion of individuals showing an onset before 
14, 18 and 25 years of age, and the 25%, 50% and 75% percentiles of the age at disorder 
onset. Thereafter, we used an empirical bootstrap approach[35] to estimate the 95% 
confidence intervals of age at onset. 
Additional sensitivity analyses were performed. First, we repeated the analyses for 
specific mental disorders, pre-selected on the basis of their epidemiological and clinical 
relevance: attention deficit/hyperactivity disorder (ADHD), autism spectrum disorder 
(ASD), generalised anxiety disorder (GAD), panic disorder, separation anxiety disorder, 
specific phobia, social anxiety disorder, obsessive-compulsive disorder (OCD), disorders 
due to use of alcohol, disorders due to use of cannabis, anorexia nervosa, bulimia nervosa, 
binge eating disorder, depressive disorders, bipolar or related disorders, acute and 
transient psychotic disorders (ATPD), schizophrenia, and post-traumatic stress disorder 
(PTSD). Second, we repeated analyses for any disorder, stratifying by onset definition 
(i.e., first symptoms, first diagnosis, first hospitalisation). Third, we repeated the analyses 
for any disorder stratifying by sex. Finally, we compared the median age at onset between 
each pair of specific mental disorders, counting the proportion of bootstrapped 
randomizations in which the median age at onset of one disorder was larger than the 
median age of the other disorder (alpha=0.05, two-sided). 
For all analyses, we required ≥2 studies to estimate the histogram and to apply the 
bootstrap procedure. For full details regarding the statistical analysis, see e-methods. 
 
RESULTS 
Literature search and database 
We identified 5,442 possible publications after removing duplicates, of which 4,504 were 
excluded after title/abstract screening. An additional 746 publications were excluded after 
full-text review (see e-Figure 1 and supplementary material -e-table 3- for full details). 
For characteristics of the 192 included studies (birth cohort studies=15, cross-sectional 
studies=150, incidence studies=27), see e-table 4. These studies were comprised of data 
from 708,561 individuals, all of whom were diagnosed with a mental disorder. Overall, 
54 studies were set in U.S., 23 studies in multiple countries, 11 in Australia, ten in 
Finland, eight in Germany, six each in Canada and the Netherlands, five in China, 
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Denmark, South Africa, Spain, United Kingdom, four in Israel, South Korea, Sweden, 
three in Ethiopia, Mexico, New Zealand, Nigeria, Switzerland, Taiwan, two in France, 
Iraq, Singapore, and one study each in additional countries. 
 
There were insufficient studies for inclusion on catatonia, dissociative disorders, 
elimination disorders, disorders of bodily experience, impulse-control disorders, 
disruptive behaviour or dissocial disorders, paraphilic disorders, factitious disorders, 
neurocognitive disorders, and disorders associated with pregnancy 
childbirth/puerperium. 
 
Global age at onset across diagnostic spectra of mental disorders 
The proportion of individuals with age at onset before 14, 18 and 25 years of age and 
peak age at onset for diagnostic spectra (co-primary outcome measures) are reported in 
table 1. Overall, before age 14, 18, and 25 years, a disorder had already emerged in 34.6%, 
48.4%, and 62.5% of individuals (Table 1). 
Corresponding figures were, respectively, for neurodevelopmental disorders: 61.5%, 
83.2%, 95.8%, for anxiety/fear-related disorders: 38.1%, 51.8%, 73.3%, for obsessive-
compulsive/related disorders: 24.6%, 45.1%, 64.0%, for feeding/eating disorders: 15.8%, 
48.1%, 82.4%, for disorders specifically associated with stress: 16.9%, 27.6%, 43.1%, for 
substance use/addictive behavior disorders: 2.9%, 15.2%, 48.8%, and for schizophrenia-
spectrum/primary psychotic disorders: 3%, 12.3%, 47.8%, for personality 
disorders/traits: 1.9%, 9.6%, 47.7%, and for mood disorders: 2.5%, 11.5%, 34.5%. 
Curves representing the median, 25th, and 75th percentiles and peak age at onset for mental 
disorder spectra are reported in Figures 1-4. The peak and median age at onset for any 
mental disorder were 14.5 years and 18 years. The earliest age peaks of disorder onset 
were: neurodevelopmental disorders (peak=5.5/median=12 years), anxiety/fear-related 
disorders (peak=5.5/median=17 years), obsessive-compulsive/related disorders 
(peak=14.5/median=18 years), feeding/eating disorders (peak=15.5/median=18 years), 
disorders specifically associated with stress (peak=15.5/median=30 years), substance 
use/addictive behaviour disorders (peak=19.5/median=25 years), schizophrenia-
spectrum/primary psychotic and personality disorders/traits (peak=20.5/median=25 
years), and mood disorders (peak=20.5/median=31 years). Second age peaks emerged for 
any mental disorder at (peak=30.5 years), anxiety/fear-related disorders (peak=15.5 
years), obsessive-compulsive/related disorders (peak=49.5 years), disorders specifically 
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associated with stress (peaks=30.5 and 49.5 years), and substance use/addictive behaviour 
disorders (peak=44.5 years). 
 
Sensitivity analyses 
The proportion of individuals with age at onset before 14, 18 and 25 years of age for 
specific mental disorders is reported in table 1. Overall, the proportion of patients 
developing disorders before age 25 is more than nine out of ten for autism spectrum 
disorder and ADHD; nine out of ten for social anxiety disorder; around eight out of ten 
for specific phobia/separation anxiety disorders and anorexia nervosa; seven to eight out 
of ten for binge eating disorders; six to seven out of ten for OCD and disorders due to use 
of cannabis; four to five out of ten for disorders due to use of alcohol, schizophrenia, 
PTSD, panic disorder, and personality disorders; three to four out of ten for GAD, 
bipolar/related disorders, and depressive disorders; and two out of ten for acute and 
transient psychotic disorder. The curves representing the peak age at onset for specific 
mental disorders are presented in e-figures 2-15. 
As reported in Table 2, the age at onset was mostly similar between males and females, 
although there was a trend towards younger ages for males in disorders due to substance 
use or addictive behaviors (median=4 years earlier), mood disorders (median=2 years 
earlier) or schizophrenia-spectrum and primary psychotic disorders (median=1 year 
earlier). Similarly, there were little differences in age at onset among studies where onset 
was defined according to first symptoms, first diagnosis or first hospitalization, although 
there was a trend towards younger ages for first symptoms than for first diagnosis in 
disorders due to substance use/addictive behaviors (median symptoms 9 years earlier), 
mood disorders (median 8 years earlier), anxiety and fear-related disorders (median 3 
years earlier). For schizophrenia-spectrum and primary psychotic disorders, we observed 
a trend from symptoms to hospital admission (median a year later) to diagnosis (median 
another year later). There were other minor differences in disorders with fewer (<10) 
separate studies for sex or onset definition, for which we suggest caution as the 
estimations may be less accurate. 
As shown in e-table 5, the age at onset of mental disorders maps on a continuum, with 
the earliest onset for neurodevelopmental disorders, separation anxiety disorders and 
specific phobia, followed by social anxiety and OCD later, later still, anxiety disorders, 






This is the first large-scale epidemiological meta-analysis that includes all available 
general population birth, cross-sectional and incidence studies investigating the age at 
onset of any ICD/DSM-mental disorders. Overall, the global onset of the first mental 
disorder occurs before age 14 in one-third of individuals, age 18 in almost half (48.4%), 
and before age 25 in half (62.5%), with a peak/median age at onset of 14.5/18 years across 
all mental disorders. However, there was significant variability in global age at onset and 
peak age across mental disorders. These findings can inform the timing and resource 
allocation regarding early intervention and preventive approaches. 
 
To our best knowledge, this study is the first fully epidemiological and largest[36–39] 
meta-analysis on age at onset of mental disorders globally. It also represents the most 
comprehensive approach, encompassing all ICD-11 diagnostic spectra for which we 
found eligible studies, allowing comparative transdiagnostic analyses across different 
categories of mental disorders[40, 41]. Furthermore, per protocol, high-quality 
population-level studies were included that are less likely to be affected by biases, 
meeting previous methodological recommendations[31]. Moreover, data from all 
continents of the world were available, providing global estimates on the age at onset of 
mental disorders. Importantly, the statistical approach of this meta-analysis provides an 
estimate of age at disorder onset distribution throughout the lifespan, going beyond mere 
centrality estimates. 
The meta-epidemiologic results of this work show that mental disorders have onset when 
dramatic biological changes in the brain occur, from childhood, through adolescence, to 
adulthood, that involve grey-matter density, cerebral metabolic rate, synaptic density, 
white matter growth and myelination[42]. The in-depth, robust epidemiological evidence 
provided here has several clinical implications. Firstly, the onset of the first mental 
disorder before age 14, 18 and 25 in one third, half and 62.5% and peak/median age of 
15.5/18 years demonstrate that adult mental disorders originate early during the 
neurodevelopmental phases of life and peak, in pooled mental disorders, by mid to late 
adolescence[43–45]. Given that mental disorders are one of the five most common 
ailments leading to morbidity, mortality and dysfunction among young people 
worldwide[46], the current findings are relevant to policymakers and healthcare 
providers. These results suggest that the next generation of mental health research should 
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prioritize designing and funding global early interventions[5, 47] and indicated, selective 
and/or universal preventive interventions for mental disorders during mid/late 
adolescence and young adulthood that are currently lacking[8].  
Secondly, this study provides disorder-specific estimates of age at disorder onset that 
impacts mental health service configuration and delivery. For about half of mental 
disorders (Table 2), disorder onset occurs well before age 18; occurring before age 14 for 
the vast majority of ADHD, ASD, specific phobia and separation anxiety disorder. For 
these disorders, good mental health promotion, along with  preventive and early 
intervention approaches need to target these neurodevelopmental periods, mainly during 
pre-school and primary school periods. Many of the risk and protective factors that impact 
the neurodevelopment of individuals with these disorders are known[48–54], and some 
of them may even impact the pre or perinatal phases[55]. A recent meta-umbrella review 
(i.e. a synthesis of systematic reviews of meta-analyses) has summarised risk and 
protective factors (beyond genetics) in a comprehensive atlas[56]. Importantly, targeting 
the neurodevelopmental phase has the potential to accommodate multi-endpoint 
numerators across mental disorders that are essential to better justify the denominator of 
efforts and costs for preventive and early intervention[8]. Higher age at disorder onset 
emerged from our study for another cluster of mental disorders, i.e., social anxiety, OCD, 
and trauma-related disorders, followed by a third and larger cluster, including panic 
disorder, GAD, eating disorders, disorders due to use of alcohol and cannabis, depressive 
and bipolar and related disorders. For these clusters, good mental health promotion, 
prevention and early intervention could be delivered in primary and secondary 
schools[57–59]. The fourth cluster of disorders included personality disorders and 
schizophrenia-spectrum and primary psychotic disorders. For these disorders, secondary 
schools and colleges could become the most important setting for mental health 
promotion, prevention and early intervention. Importantly, the diagnosis of personality 
disorder is artifactually delayed by diagnostic criteria allowing diagnosis after age 18, but 
clinically relevant symptoms occur earlier.  
For all four clusters, promotion of good mental health (indicated, selective and/or 
universal) prevention and early intervention should ideally be delivered in an integrated 
fashion that encompasses schools, and paediatricians/general practitioners, emergency 
departments, mental health settings, as well as the general community [60]. Overall, this 
study shows that any lower age threshold limiting access to mental health promotion 
campaigns or preventive or early interventions mental health programs is not supported 
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by our meta-epidemiological evidence. Conversely, lower age thresholds that divide the 
education and training of mental health specialists or clinical services deprive individuals 
who develop mental disorders of continuity of care. Divisions fragment pathways to care 
and continued treatment from childhood through adolescence into adulthood (see 
below)[61]. Our recommendation for mental health services of the future would allow 
soft entry points, set no lower age threshold, and loosen lower age intake criteria[62]. For 
example, an indicated prevention and early intervention model of care for mood disorders, 
personality disorders, and schizophrenia-spectrum/primary psychotic disorders should 
ideally integrate low-threshold entry points for individuals of age younger than 18, 
supplemented by systematic promotion of good mental health, proactive screening for 
risk of developing specific mental disorders within the four temporal clusters identified 
above, and deliver needs-based care[63–65].  
 
Thirdly, a further, broader clinical implication of these results is that it demonstrates that 
age 18 as an intake threshold for adult mental health services is artificial and not based 
on global epidemiological evidence (nor on biological evidence of age when major brain 
changes occur[42]). To the best of our knowledge, mental health specialist training and 
mental health services in most parts of the world, including North America, Australia, 
most European countries, including Italy, Germany, UK, are divided between 
child/adolescent psychiatry and adult psychiatry. Given that the vast majority of mental 
disorders diagnoses seen in adulthood show a peak of onset before age 18, such a 
bifurcated mental health system is not evidence-based and may disadvantage individuals 
who develop mental disorders from accessing and receiving adequate and continuous 
care[66]. Moreover, most psychiatry training programs fail to target the transition period 
from childhood and adolescence to adult psychiatry[67]. Although many mental health 
services have tried to address this discontinuity of care[67, 68], significant gaps remain. 
Future mental health reforms could leverage and refine clinical high-risk services for 
young people at risk of psychosis, which typically accept referrals aged 14 to 35 years 
and therefore provide essential transitional care to this vulnerable young population[17, 
61, 69]. 
 
This study has several limitations. First, data were too sparse to calculate country-specific 
estimates. However, the database included many countries worldwide, and, therefore, the 
estimates provided are largely representative of the global general population. Second, 
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the 95% confidence interval for some estimates were broad since analyses for some 
disorders were based on few studies. Third, data were heterogeneous, making traditional 
meta-analytic techniques unfeasible. We, therefore, applied advanced meta-analytic 
techniques, including bootstrap methods that helped to address this shortcoming and 
provide unified outcomes across all mental disorders. Fourth, our quality assessment was 
non-standardized because appropriate validated measures were not available. However, 
we per protocol included the highest-quality studies to study age at onset according to 
previous recommendations[31]. Fifth, the definition of age at disorder onset was 
heterogeneous; we addressed this issue via sensitivity analyses. Sixth, we were not able 
to account and differentiate among comorbid and standalone diagnoses. Finally, caution 
is needed when comparing peaks (e.g. between symptoms and diagnosis), in particular 
when the peak curves are different. 
 
CONCLUSIONS 
The meta-analytic, global, epidemiological evidence provided challenges the current 
mental health care system that artificially separates child/adolescent and adult mental 
health services, providing strong epidemiologic evidence for the global implementation 
of integrated models of mental health promotion and preventive/early intervention care 
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Figure 1. Median age at onset of mental disorders 
 
Legend. The line indicates the median age at onset of mental disorders (ICD-11 diagnostic blocks or spectra above, specific mental disorders below), the bar indicates the 25th and 75th 
percentiles. 
ICD-11 blocks of mental disorders. Anxiety and fear: anxiety and fear-related disorders; Feeding and eating: feeding or eating disorders; Mood: mood disorders; OCD related: obsessive-
compulsive or related disorders; Personality, personality disorders; Schizophrenia spectrum: schizophrenia-spectrum and primary psychotic disorders; Stress: disorders specifically associated 
with stress; Substances: disorders due to substance use or addictive behavior. 
ICD-11 specific mental disorders. Acute psychosis: acute and transient psychotic disorder; ADHD: attention deficit hyperactivity disorder; Alcohol: disorder due to alcohol; Anorexia: anorexia 
nervosa; Autism: autism spectrum; Binge: binge eating disorder; Bipolar: bipolar or related disorders; Bulimia: bulimia nervosa; Cannabis: disorder due to use of cannabis; Depressive: depressive 
disorders; GAD: generalised anxiety disorder; OCD: obsessive-compulsive disorder; Panic: panic disorder; Phobia: specific phobia; PTSD: post-traumatic stress disorder; Separation: separation 
anxiety disorder; Social: social anxiety disorder.nervosa; Cannabis: disorder due to use of cannabis; Depressive: depressive disorders; GAD: generalised anxiety disorder; OCD: obsessive-
compulsive disorder; Panic: panic disorder; Phobia: specific phobia; PTSD: post-traumatic stress disorder; Separation: separation anxiety disorder; Social: social anxiety disorder.
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Figure 2. Epidemiological proportion (y axis) and peak age at onset (red line) for any mental disorders in the 





Figure 3. Epidemiological proportion (y axis) and peak age at onset (red line) for neurodevelopmental, 
anxiety and fear-related, obsessive-compulsive related, and feeding or eating disorders (ICD-11 blocks) in 










Figure 4. Epidemiological proportion (y axis) and peak age at onset (red line) for disorders due to substance 
use or addictive behaviour, personality, mood, and schizophrenia-spectrum and primary psychotic disorders 











Table 1. Meta-analytic epidemiological estimates of age at onset of mental disorder (ICD-11 blocks highlighted in grey) in the general population 
 N of Samples Peak age at onset (years) 
Proportion 
onset by 14 
years 
Proportion 
onset by 18 
years 
Proportion 
onset by 25 
years 
p25 Median p75 
Any mental disorder 14 14.5 34.6% 48.4% 62.5% 11 18 34 
Neurodevelopmental disorders 21 5.5 61.5% 83.2% 95.8% 7 12 16 
Autism spectrum disorder 2 5.5 72.4% 89.8% 94.8% 5 9 14 
Attention deficit hyperactivity disorder 12 9.5 56.8% 73.0% 91.8% 8 12 18 
Anxiety and fear-related disorders 73 5.5 38.1% 51.8% 73.3% 9 17 25 
Specific phobia / Separation anxiety disorder 22 5.5 72.4% 75.0% 80.4% 5 8 17 
Social anxiety disorder 42 14.5 50.9% 79.1% 87.5% 9 13 17 
Panic disorder 22 15.5 8.2% 22.5% 45.7% 18 26 36 
Generalised anxiety disorder 24 15.5 8.6% 20.4% 33.0% 20 32 42 
Obsessive-compulsive related disorders 20 14.5 24.6% 45.1% 64.0% 14 19 29 
Obsessive-compulsive disorder 20 14.5 24.6% 45.1% 64.0% 14 19 29 
Feeding or Eating disorders 11 15.5 15.8% 48.1% 82.4% 15 18 23 
Anorexia nervosa 8 15.5 18.2% 55.2% 78.7% 14 17 22 
Binge eating disorder 5 19.5 12.3% 34.5% 73.5% 16 20 25 
Trauma related disorders 16 15.5 16.9% 27.6% 43.1% 17 30 48 
Post-traumatic stress disorder 16 15.5 16.9% 27.6% 43.1% 17 30 48 
Disorders due to substance use or addictive behaviours 58 19.5 2.9% 15.2% 48.8% 20 25 41 
Disorder due to use of cannabis 10 19.5 3.2% 17.5% 64.6% 19 22 29 
Disorder due to use of alcohol 44 19.5 4.2% 18.3% 44.8% 19 27 43 
Schizophrenia-spectrum and primary psychotic disorders 36 20.5 3.0% 12.3% 47.8% 20 25 34 
Schizophrenia 25 20.5 2.0% 8.2% 47.4% 21 25 35 
Acute and transient psychotic disorder 2 18.5 1.8% 6.6% 20.6% 27 35 45 
Personality disorders 6 20.5 1.9% 9.6% 47.7% 20 25 33 
Mood disorders 79 20.5 2.5% 11.5% 34.5% 21 31 46 
Depressive disorders 62 19.5 3.1% 13.2% 36.9% 21 30 44 
Bipolar or related disorders 40 19.5 5.1% 13.7% 32.0% 22 33 49 
 




Table 2. Age at onset by onset definition and by sex for mental disorders (ICD-11 blocks highlighted in grey). 
Disorder Onset definition/Sex Samples 
Peak age at onset 
(years) 
Proportion 
onset by 14 
years 
Proportion 
onset by 18 
years 
Proportion 
onset by 25 
years 
p25 Median p75 
Any mental disorder First symptoms 5 4.5 41.5% 50.0% 69.5% 8 18 27 
Any mental disorder First diagnosis 6 5.5 38.6% 54.1% 68.3% 9 16 33 
Neurodevelopmental disorders First symptoms 8 5.5 40.4% 56.0% 62.9% 7 16 - 
Neurodevelopmental disorders First diagnosis 11 5.5 61.3% 82.6% 95.0% 7 12 16 
Neurodevelopmental disorders Female 5 9.5 59.6% 74.5% 82.2% 7 12 18 
Neurodevelopmental disorders Male 4 9.5 67.0% 81.2% 89.0% 7 11 15 
Autism spectrum disorder First diagnosis 2 5.5 72.4% 89.8% 94.8% 5 9 14 
Autism spectrum disorder Female 2 5.5 80.1% 92.3% 96.0% 5 8 12 
Autism spectrum disorder Male 2 5.5 80.6% 92.4% 96.0% 5 8 12 
Attention deficit hyperactivity disorder First symptoms 2 4.5 99.8% 99.8% 100.0% 4 5 7 
Attention deficit hyperactivity disorder First diagnosis 9 9.5 56.2% 72.5% 91.8% 8 12 18 
Attention deficit hyperactivity disorder Female 3 9.5 65.0% 81.0% 95.2% 8 11 16 
Attention deficit hyperactivity disorder Male 3 9.5 67.5% 81.3% 94.9% 8 11 15 
Anxiety and fear-related disorders First symptoms 31 4.5 45.1% 59.9% 71.9% 5 15 27 
Anxiety and fear-related disorders First diagnosis 18 5.5 35.5% 48.5% 71.0% 9 18 26 
Anxiety and fear-related disorders Female 6 19.5 11.6% 22.9% 45.8% 18 26 40 
Anxiety and fear-related disorders Male 7 19.5 21.8% 31.4% 52.4% 15 24 37 
Specific phobia / Separation anxiety disorder First symptoms 12 4.5 71.2% 77.6% 82.8% 5 7 16 
Specific phobia / Separation anxiety disorder First diagnosis 9 5.5 72.1% 76.0% 85.0% 6 9 16 
Specific phobia / Separation anxiety disorder Female 2 4.5 58.3% 60.6% 68.2% 5 8 30 
Specific phobia / Separation anxiety disorder Male 2 5.5 50.0% 53.6% 70.2% 7 13 26 
Social anxiety disorder First symptoms 9 14.5 54.6% 75.4% 81.5% 7 13 17 
Social anxiety disorder First diagnosis 7 14.5 47.5% 77.1% 85.4% 10 14 17 
Panic disorder First symptoms 10 15.5 11.9% 28.9% 56.4% 17 22 32 
Panic disorder First diagnosis 10 39.5 9.3% 20.7% 43.8% 19 27 40 
Panic disorder Female 3 20.5 20.8% 29.0% 53.4% 16 24 31 
Panic disorder Male 3 15.5 16.1% 32.9% 56.9% 16 22 31 
Generalised anxiety disorder First symptoms 13 15.5 9.4% 21.3% 32.8% 19 39 52 
Generalised anxiety disorder First diagnosis 8 45.5 7.5% 15.2% 27.3% 23 34 48 
Obsessive-compulsive related disorder First symptoms 6 14.5 23.4% 48.1% 71.6% 14 18 25 
Obsessive-compulsive related disorder First diagnosis 11 14.5 24.1% 44.1% 56.4% 14 20 35 
Obsessive-compulsive related disorder Female 4 15.5 16.9% 32.8% 55.5% 16 23 30 
Obsessive-compulsive related disorder Male 4 10.5 27.7% 42.6% 67.1% 13 20 27 
Feeding or eating disorders First symptoms 4 15.5 10.2% 40.1% 77.2% 16 19 24 
Feeding or eating disorders First diagnosis 7 15.5 16.0% 44.7% 74.2% 15 18 25 
Feeding or eating disorders Female 4 14.5 23.0% 54.8% 76.5% 14 17 23 
Feeding or eating disorders Male 4 14.5 37.6% 67.3% 86.9% 12 15 19 
Anorexia nervosa First symptoms 3 15.5 20.4% 59.9% 89.0% 14 16 20 
Anorexia nervosa First diagnosis 5 15.5 10.6% 37.3% 54.6% 16 22 87 
Binge eating disorder First symptoms 2 19.5 15.5% 31.4% 70.4% 16 20 28 
Binge eating disorder First diagnosis 3 15.5 8.2% 34.5% 73.5% 16 20 25 
Trauma-related disorders First symptoms 6 25.5 13.3% 23.4% 33.0% 18 33 48 
Trauma-related disorders First diagnosis 7 15.5 19.4% 31.3% 46.1% 15 29 46 
24 
 
Disorders due to substance use or addictive behaviours First symptoms 34 15.5 8.2% 39.1% 78.4% 16 19 23 
Disorders due to substance use or addictive behaviours First diagnosis 21 20.5 1.6% 9.5% 41.3% 21 28 43 
Disorders due to substance use or addictive behaviours Female 11 20.5 0.8% 5.7% 34.3% 22 31 45 
Disorders due to substance use or addictive behaviours Male 12 20.5 2.5% 13.2% 41.8% 20 27 41 
Disorder due to use of cannabis First symptoms 2 20.5 5.8% 8.5% 17.2% 30 44 63 
Disorder due to use of cannabis First diagnosis 5 20.5 3.0% 16.7% 66.0% 19 22 27 
Disorder due to use of cannabis Female 3 20.5 4.0% 15.9% 61.3% 19 23 28 
Disorder due to use of cannabis Male 3 20.5 3.3% 14.6% 61.5% 19 23 28 
Disorder due to use of alcohol First symptoms 25 15.5 8.4% 39.2% 71.9% 16 19 26 
Disorder due to use of alcohol First diagnosis 15 20.5 0.9% 4.5% 27.1% 24 36 47 
Disorder due to use of alcohol Female 9 44.5 0.1% 1.5% 16.2% 29 40 50 
Disorder due to use of alcohol Male 9 15.5 2.9% 13.8% 29.0% 22 36 47 
Schizophrenia-spectrum and primary psychotic disorders First symptoms 11 24.5 6.0% 15.0% 51.1% 20 24 29 
Schizophrenia-spectrum and primary psychotic disorders First diagnosis 10 20.5 2.1% 11.2% 45.3% 20 26 39 
Schizophrenia-spectrum and primary psychotic disorders First hospitalization 14 24.5 12.9% 17.8% 45.4% 20 25 32 
Schizophrenia-spectrum and primary psychotic disorders Female 18 20.5 2.4% 10.0% 45.4% 21 26 35 
Schizophrenia-spectrum and primary psychotic disorders Male 18 20.5 7.6% 15.9% 49.9% 20 25 32 
Schizophrenia First symptoms 8 24.5 7.2% 18.0% 54.8% 19 24 28 
Schizophrenia First diagnosis 8 20.5 0.9% 6.5% 43.7% 21 26 39 
Schizophrenia First hospitalization 10 25.5 30.2% 34.5% 52.0% 11 24 31 
Schizophrenia Female 16 20.5 2.5% 8.3% 45.7% 21 25 33 
Schizophrenia Male 16 20.5 6.0% 11.6% 48.7% 20 25 31 
Acute and transient psychotic disorder First diagnosis 2 19.5 1.8% 6.6% 20.6% 27 35 45 
Personality disorders First symptoms 2 5.5 93.6% 96.3% 96.5% 5 7 10 
Personality disorders First diagnosis 4 20.5 2.2% 10.0% 49.2% 20 25 32 
Personality disorders Female 3 20.5 0.8% 5.5% 37.7% 22 27 37 
Personality disorders Male 3 20.5 14.4% 19.6% 47.7% 19 25 34 
Mood disorders First symptoms 32 19.5 12.2% 26.1% 51.7% 17 24 36 
Mood disorders First diagnosis 40 20.5 2.2% 10.7% 33.3% 22 32 48 
Mood disorders Female 22 20.5 1.0% 5.4% 22.0% 26 40 56 
Mood disorders Male 22 20.5 3.4% 9.0% 24.9% 25 38 55 
Depressive disorder First symptoms 22 15.5 10.2% 25.9% 47.0% 17 26 34 
Depressive disorder First diagnosis 35 19.5 2.5% 12.0% 35.8% 21 31 46 
Depressive disorder Female 18 20.5 1.1% 5.9% 22.4% 26 40 55 
Depressive disorder Male 17 20.5 3.5% 9.0% 24.5% 25 38 54 
Bipolar or related disorder First symptoms 15 19.5 10.3% 30.9% 68.8% 16 21 26 
Bipolar or related disorder First diagnosis 24 20.5 0.6% 2.7% 18.8% 28 40 52 
Bipolar or related disorder Female 8 19.5 1.7% 7.8% 23.3% 26 39 52 
Bipolar or related disorder Male 7 49.5 4.4% 12.2% 24.5% 25 39 52 
Legend. p25, p75, 25th and 75 th percentile. Secondary peaks are between parentheses. Curves were calculated when at least two studies were included for each 
ICD-11 block or disorder. Bootstrap comparisons were run when at least five studies were included for each disorder; no significant difference emerged by sex 
or onset definition. 
